Friday, July 10, 2026
🇺🇸 FDA

pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease

Otsuka Beijing Research

Otsuka Beijing Research Institute

Otsuka Beijing Research clinical programs — 33 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
33
Drugs
25
Patents
0
All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Otsuka Beijing Research projects

33 ClinicalTrials.gov programs sponsored by Otsuka Beijing Research.

Otsuka Beijing Research has 33 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

33 programs

Clinical programs

  1. 156-201-00307

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  2. 20-AVP-786-306

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  3. AVP-786 matching placebo, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  4. Aripiprazole

    Otsuka Beijing Research Institute

    Bipolar I

    phase 3 small molecule completed

    1 trial

  5. Aripiprazole IM Depot

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  6. Delamanid + OBR

    Otsuka Beijing Research Institute

    Multidrug-resistant Tuberculosis

    phase 3 small molecule completed

    1 trial

  7. Escitalopram

    Otsuka Beijing Research Institute

    Major Depressive Disorder (MDD)

    phase 3 small molecule terminated

    1 trial

  8. JNT517-301

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  9. Sibeprenlimab 400 mg

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  10. Sibeprenlimab 400 mg s.c. Q4weeks

    Otsuka Beijing Research Institute

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  11. Tolvaptan

    Otsuka Beijing Research Institute

    Autosomal Recessive Polycystic Kidney Disease

    phase 3 small molecule active

    1 trial

  12. Tolvaptan

    Otsuka Beijing Research Institute

    Cardiac Edema

    phase 3 small molecule completed

    1 trial

  13. DIABECELL(R)

    Otsuka Beijing Research Institute

    Type 1 Diabetes

    phase 2 other completed

    1 trial

  14. Delamanid

    Otsuka Beijing Research Institute

    Tuberculosis, Multidrug-Resistant

    phase 2 small molecule completed

    1 trial

  15. Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 2 small molecule completed

    1 trial

  16. JNT-517 Suspension

    Otsuka Beijing Research Institute

    Phenylketonuria

    phase 2 small molecule completed

    1 trial

  17. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  18. SPM 962

    Otsuka Beijing Research Institute

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  19. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Beijing Research Institute

    Treatment of Sjögren’s disease

    phase 2 small molecule active

    1 trial

  20. 100 mg Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 1 small molecule completed

    1 trial

  21. 323-201-00009

    Otsuka Beijing Research Institute

    Tuberculosis

    phase 1 other active

    1 trial

  22. A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

    Otsuka Beijing Research Institute

    Incomplete Response - Major Depressive Disorder (IR-MDD)

    phase 1 other active

    1 trial

  23. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

  24. OPC-108459

    Otsuka Beijing Research Institute

    Atrial Fibrillation

    phase 1 small molecule completed

    1 trial

  25. Tolvaptan 15mg or 30mg or 60mg or Placebo

    Otsuka Beijing Research Institute

    Healthy

    phase 1 small molecule completed

    1 trial

  26. VIS171-103

    Otsuka Beijing Research Institute

    Systemic lupus erythematosus, Immune-mediated focal segmental glomerulosclerosis, Alopecia Areata

    phase 1 other active

    1 trial

  27. Aripiprazole

    Otsuka Beijing Research Institute

    Schizophrenia

    approved small molecule completed

    3 trials

  28. Cilostazol

    Otsuka Beijing Research Institute

    Polyneuropathy

    approved small molecule completed

    1 trial

  29. Cilostazol

    Otsuka Beijing Research Institute

    Cerebral Infarction

    approved small molecule completed

    1 trial

  30. Procaterol

    Otsuka Beijing Research Institute

    Asthma

    approved small molecule completed

    1 trial

  31. Rebamipide

    Otsuka Beijing Research Institute

    Stomach Ulcer

    approved small molecule completed

    1 trial

  32. Tolvaptan

    Otsuka Beijing Research Institute

    Hyponatremia and Extracellular Fluid in Cirrhotic

    approved small molecule terminated

    1 trial

  33. aripiprazole

    Otsuka Beijing Research Institute

    Bipolar Disorder

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Otsuka Beijing Research have?

33 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.